OncoMatch/Clinical Trials/NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Is NCT07503808 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies IDE034 for esophageal squamous cell carcinoma.
Treatment: IDE034 — This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Ovarian Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Prostate Cancer
Small Cell Lung Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: CD276 expression
Required: PTK7 expression
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior antitumor therapy
radiologically progressed or recurred on at least one line of therapy or is intolerant to additional effective standard therapies
Cannot have received: B7-H3 antibody-drug conjugate
prior treatment with B7-H3...antibody-drug conjugate (ADC)
Cannot have received: PTK7 antibody-drug conjugate
prior treatment with...PTK7 antibody-drug conjugate (ADC)
Cannot have received: topoisomerase I inhibitor
prior treatment with a topoisomerase I inhibitor (TOP1i), including an ADC with a TOP1i payload, within 6 months of first dose of IMP
Cannot have received: chemotherapy
received chemotherapy within 3 weeks of first dose of IMP
Cannot have received: immunotherapy
immunotherapy or biologic targeted antitumor treatments within 3 weeks before the first dose of IMP
Cannot have received: investigational product
other investigational products within 4 weeks of first dose of IMP
Cannot have received: radiation therapy
received radiotherapy within 2 weeks prior to study entry
Lab requirements
Blood counts
adequate bone marrow
Kidney function
Liver function
Cardiac function
clinically significant cardiac abnormalities and/or cerebrovascular disease (stroke) within 6 months before the first dose [excluded]
adequate bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Texas LLC - Austin · Austin, Texas
- NEXT Texas LLC - Houston · Houston, Texas
- NEXT Texas LLC - Dallas · Irving, Texas
- NEXT Texas LLC - San Antonio · San Antonio, Texas
- NEXT Texas LLC - Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify